A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Reprogram a bacterial defence enzyme with a short RNA, and you can cut any gene you choose.
Scientists took a defence system that bacteria use against viruses and turned it into cheap, precise “scissors” that can find and cut any chosen gene.
The idea, unpacked
Bacteria have their own immune system. When a virus attacks, they save a small piece of its DNA as a kind of mugshot, then make a matching strand of RNA that guides a cutting protein — Cas9 — to chop up that exact sequence if the virus ever returns. The guide RNA is essentially a search term, and Cas9 is the blade.
Where it came from
For years, CRISPR was a curiosity of bacterial biology. The breakthrough was realising you can write your own search term. Swap in a guide RNA that matches any gene you like — in a plant, a mouse, or a human cell — and Cas9 will travel to that precise spot in the three-billion-letter genome and make a cut. The cell then tries to repair the break, and scientists can use that moment to switch a gene off or paste in a corrected version. Older gene-editing methods meant building a complicated custom protein for every target. CRISPR just needs a new snippet of RNA — so cheap and simple that labs everywhere adopted it almost overnight, and Charpentier and Doudna shared the 2020 Nobel Prize in Chemistry.
Why it mattered
CRISPR put precise gene editing within reach of ordinary laboratories, transforming biology and medicine. It's now being used to develop treatments for inherited diseases like sickle-cell anaemia, to engineer hardier crops, and to study how genes work — which is also why it raises serious ethical questions about editing human life.
Two locks, not one
Aiming the scissors isn't quite as simple as “any address.” Cas9 first checks for a tiny three-letter pass code in the DNA — a “PAM,” the letters NGG — sitting right next to the target. No pass code, no cut, even if the guide matches perfectly. Then the guide has to pair up with the DNA letter by letter, and a mismatch in the stretch nearest the pass code is enough to stop it. Try writing a guide and watch Cas9 decide whether to cut.
What came next
CRISPR moved from the lab bench to the clinic with startling speed. In 2023 the first CRISPR-based therapy was approved, curing some patients of sickle-cell disease by editing their own blood cells. Newer versions can rewrite a single DNA letter without even cutting both strands. The same power is why the world is still debating where to draw the line — especially around editing embryos, whose changes would pass to every future generation.
We engineered the two RNAs into a single RNA chimera and show that it directs sequence-specific Cas9 dsDNA cleavage. Our study reveals a family of endonucleases that use dual RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-programmable genome editing.